Debevoise Adds Paul D. Rubin, Leading FDA/FTC Regulatory Lawyer, to Healthcare Group

5 September 2017

Debevoise & Plimpton LLP today announced that Paul D. Rubin has joined the Washington, D.C. office as a partner and member of the firm’s Healthcare Group. With more than 25 years of experience, Mr. Rubin represents FDA-regulated drug, device and consumer product companies on a wide range of issues ranging from strategic regulatory counseling to complex compliance and enforcement matters. He also conducts regulatory due diligence for private equity funds and strategic acquirers in corporate transactions.

In addition to his FDA practice, Mr. Rubin has substantial experience helping clients navigate complex advertising and promotion-related issues, including FTC investigations, disputes before the National Advertising Division of the Better Business Bureau (NAD) and advertising lawsuits under Section 43(a) of the Lanham Act. Mr. Rubin also has considerable experience advising consumer product companies on CPSC-related compliance, including Section 15(b) submissions and “Fast Track Recalls.”

“We are thrilled to welcome Paul to Debevoise,” said Michael W. Blair, the firm’s Presiding Partner. “Healthcare is a strategic priority industry for our firm and Paul’s deep experience will strengthen our ability to help our clients navigate this uncertain market.”

“As a preeminent regulatory lawyer, Paul’s expertise and market savvy will prove invaluable for clients seeking to stay ahead in today’s evolving healthcare industry. His insights will further complement our experienced, growing Healthcare Group,” said Mark P. Goodman, partner and leader of the firm’s Healthcare Practice. “We are very pleased to have Paul on our team.”

“With Paul’s addition, the Debevoise Healthcare Group has even greater capacity to cover the full array of regulatory, compliance and related risk issues relevant to healthcare and life sciences transactions,” said partner Andrew L. Bab, co-head of the Healthcare Group. “This will allow us to seamlessly structure deals in ways that minimize risk, and counsel clients on how to factor risk into transactions in a commercial, practical manner.”

Throughout his career, Mr. Rubin has focused his practice on FDA/FTC regulatory matters, most recently serving as a partner in the life sciences group of an international law firm in Washington, D.C.

“Over the years I have been fortunate to work with Debevoise lawyers on numerous projects, and have been uniformly impressed by their legal knowledge and practical business acumen. I am honored to join the Debevoise team and look forward to working with this talented group of lawyers to help clients prepare and adapt to ongoing changes in the regulatory environment,” said Mr. Rubin. “The Debevoise Healthcare Group has a reputation for excellence and the firm is universally praised for its collaborative and collegial culture.”

Mr. Rubin earned his J.D. in 1992 from the University of Pennsylvania Law School, cum laude, and received his B.S. in Economics from the Wharton School of Business, magna cum laude, in 1989.

Debevoise’s Healthcare Group handles significant transactions and regulatory and litigation matters for pharmaceutical companies, medical device companies, hospitals, financial sponsors, financial advisors and other key players in the industry. The Group’s transactional work includes mergers and acquisitions, financings, securities offerings, licensing, development and commercialization transactions. The Group’s litigation work spans investigations by U.S. government agencies; a broad range of civil litigation, including state and federal qui tam actions and class action litigation; compliance with U.S. regulatory requirements; advising boards of directors; and the defense of intellectual property rights.

About Debevoise & Plimpton LLP

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.